Rabbit Recombinant Monoclonal eNOS antibody. Suitable for IP, WB and reacts with Human, Mouse, Rat samples. Cited in 43 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IP | WB | |
---|---|---|
Human | Tested | Tested |
Mouse | Expected | Tested |
Rat | Expected | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 | Notes We recommend using freshly made lysate in western blot testing to get stronger band and avoid high background. |
Species Rat | Dilution info 1/1000 | Notes We recommend using freshly made lysate in western blot testing to get stronger band and avoid high background. |
Species Human | Dilution info 1/1000 | Notes We recommend using freshly made lysate in western blot testing to get stronger band and avoid high background. |
Select an associated product type
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway (PubMed:1378832). NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C. Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.
Nitric oxide synthase 3, Constitutive NOS, EC-NOS, NOS type III, cNOS, NOSIII, Endothelial NOS, eNOS, NOS3
Rabbit Recombinant Monoclonal eNOS antibody. Suitable for IP, WB and reacts with Human, Mouse, Rat samples. Cited in 43 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
ENOS also known as endothelial nitric oxide synthase is an enzyme important for the production of nitric oxide (NO) in blood vessels. This protein with a molecular weight of approximately 133 kDa is expressed mostly in endothelial cells. eNOS plays a mechanical role in synthesizing NO from L-arginine a process requiring cofactors such as NADPH and oxygen. The activity of eNOS can be investigated through techniques such as Western blot with specific assays like phospho-eNOS ELISA available to measure its phosphorylated forms indicating activated states of the enzyme.
ENOS contributes significantly to the regulation of vascular tone and blood flow by promoting vasodilation. It does not function alone; instead it forms complexes with other proteins to exert its full effect. eNOS activity influences the process of angiogenesis inflammation modulation and platelet aggregation. Through its ability to produce nitric oxide eNOS acts as a signaling molecule helping maintain vascular homeostasis.
ENOS is a critical player in the NO signaling pathway and interacts intricately with the PI3K/Akt pathway. Nitric oxide produced by eNOS has a role in signaling cascades that lead to vascular dilation and reduced blood pressure. The PI3K/Akt pathway regulates eNOS activity via phosphorylation enhancing NO production. Other proteins like caveolin-1 and calmodulin modulate eNOS impacting these pathways' outcomes.
ENOS is associated with cardiovascular conditions like atherosclerosis and hypertension. Dysfunction of eNOS can lead to reduced NO production impairing vasodilation and contributing to these diseases. In cardiovascular disorders eNOS interacts with proteins such as the angiotensin II type 1 receptor which can negatively impact its function exacerbating disease states. Investigating eNOS and its related proteins provides insight into potential therapeutic targets for improving cardiovascular health.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking/Dilution buffer: 5% NFDM/TBST.
eNOS is shown to be expressed in platelets, placenta, liver and kidney (UniProt entry P29474). It also plays an important role in the cardiovascular system. (PMID: 15210449 & 15936740).
All lanes: Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1: Human fetal heart lysate at 20 µg
Lane 2: Human fetal kidney lysate at 20 µg
Lane 3: Human fetal liver lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
Exposure time: 3min
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: Lane 1, 2, 3, 4, 6 and 7: 30 seconds; Lane 5: 2 minutes.
eNOS is shown to be expressed in platelets, placenta, liver and kidney (UniProt entry P29474). It also plays an important role in the cardiovascular system. (PMID: 15210449 & 15936740).
All lanes: Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1: Mouse brain lysate at 10 µg
Lane 2: Mouse heart lysate at 10 µg
Lane 3: Mouse kidney lysate at 10 µg
Lane 4: Mouse spleen lysate at 10 µg
Lane 5: Rat brain lysate at 10 µg
Lane 6: Rat heart lysate at 10 µg
Lane 7: Rat spleen lysate at 10 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
Exposure Time: Lane1: 40 seconds; Lane2: 180 seconds
The expression profile observed in HeLa is consistent with the literature (PMID: 19925457).
Negative control: HeLa (PMID: 19925457)
All lanes: Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1: HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
eNOS was immunoprecipitated from 1 mg of HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with ab199956 at 1/50 dilution. Western blot was performed from the immunoprecipitate using ab199956 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366), was used for detection at 1/10000 dilution.
Lane 1: HepG2 whole cell lysate 10 μg (Input).
Lane 2: ab199956 IP in HepG2 whole cell lysate.
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab199956 in HepG2 whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 seconds.
All lanes: Immunoprecipitation - Anti-eNOS antibody [EPR19296] (ab199956)
Predicted band size: 133 kDa
Blocking/Dilution buffer: 5% NFDM/TBST.
The expression profile observed is consistent with what has been described in the literature (PMID:17855661 & 11004215).
All lanes: Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/5000 dilution
Lane 1: HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 20 µg
Lane 2: Whole cell lysate from HepG2 cells treated with 10 μg/ml LPS for 2 hours at 20 µg
Lane 3: Whole cell lysate from HepG2 cells treated with 10 μg/ml LPS for 6 hours at 20 µg
All lanes: Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
Exposure time: 15s
Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure time: Lane 1: 1 second; Lane 2: 3 minutes.
All lanes: Western blot - Anti-eNOS antibody [EPR19296] (ab199956) at 1/1000 dilution
Lane 1: Western blot - Recombinant Human eNOS protein (Tagged) (Recombinant Human eNOS protein (Tagged) ab198066) at 0.01 µg
Lane 2: Western blot - Recombinant Human iNOS protein (Recombinant Human iNOS protein ab135010) at 0.05 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 133 kDa
Observed band size: 140 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com